A medicine costing $300,000 a year was helping slow a fatal disease in a 16-year-old Coraopolis boy, while also threatening to bankrupt his family.
Things turned worse when Highmark, the family’s health insurer, twice denied to cover the drug, which is called eteplirsen. The boy’s mother was frantic.
“I was really stunned,” Terri Ellsworth said. “I never expected that we were going to get a denial. It’s so disheartening.”
Prescription drug costs are up sharply, even for ones that have been on the market for years, eating up about 20 cents of every health care dollar and increasing by 9 percent between 2015 and 2016 alone.
“Manufacturers are launching products at higher price points,” said Sarah Marche, vice president of pharmacy services at Highmark. “And every time a new drug comes to market, the higher price point allows other manufacturers to raise prices for existing drugs.”
Ms. Ellsworth’s son, Billy, has Duchenne muscular dystrophy, which affects about one in every 3,600 boys and causes rapidly progressing muscle weakness, which often results in death by early adulthood. Cambridge, Mass.-based Sarepta Therapeutics Inc. developed eteplirsen to fix a genetic error that’s present in about 13 percent of patients with the disease.
The Food & Drug Administration approved eteplirsen in September, but required the company to do further testing to show effectiveness.
In 2011, Billy Ellsworth was among 12 boys to receive it as part of a clinical trial — and it worked to slow the disease, his mother said. The medicine fixes a genetic mistake in some people with the disease, but at a cost of $300,000 a year, Ms. Ellsworth said there was no way the family could afford it.
Ms. Ellsworth, 58, works as a kitchen and bath designer, and husband Bill, 59, is trying to rebuild a career after a family printing business folded in recent years. Moreover, prescription drug coverage for eteplirsen is spotty: Anthem, the second-biggest health insurer in the country, does not pay for it; Aetna requires pre-authorization; and the drug is under review by UPMC Health Plan.
In a Jan. 28 denial letter to the Ellsworths, Highmark cited the limited studies of the drug’s effectiveness, saying it’s “clinical benefit has not been established.”
“Continued approval for the indication may be contingent upon verification of a clinical benefit in confirmatory trials,” the Highmark letter said. Ms. Ellsworth said she didn’t need any more proof.
“He’s doing phenomenally,” Ms. Ellsworth said. “He walks. It’s really a miracle.”

Boys with the disease ages 15 to 24 generally have to use a wheelchair, according to the Centers for Disease Control and Prevention.
After rejecting coverage of the drug, Highmark on Monday agreed to pay for it, Ms. Ellsworth said. The insurer declined to discuss the reasons for the pivot citing patient confidentiality.
Clinical effectiveness and safety are primary considerations in determining whether to cover a drug, Highmark’s Ms. Marche said. It’s also key to make sure a drug is used appropriately and denials often result from inadequate information from prescribing doctors.
But there’s good news on the horizon: drug prices are expected to moderate over the next five years, according to Danbury, Conn.-based pharmacy consultant QuintilesIMS Institute, as annual increases shrink to 4 percent to 7 percent. Saturation of the market for hepatitis C treatments, which costs about $84,000 for a 12-week course, and the introduction of biosimilars are among the reasons cited for the decline in pharmacy costs.
For prescription medicines with a list price of $300,000, eteplirsen joins Boston-based Vertex Pharmaceuticals’ invacaftor, a drug that was approved in 2012 to treat cystic fibrosis. David Orenstein, who directs the cystic fibrosis center at Children’s Hospital of Pittsburgh of UPMC, has been critical of the pricing for new prescription drugs, which he worries could prevent some patients from getting treatment.
“It certainly appears that a big part of the price is just the drug companies wringing as much money out of the system as they can get away with,” Dr. Orenstein said. “I don’t know what the right price would be, but some of these prices are clearly driven by what the market will bear.”
Kris B. Mamula:kmamula@post-gazette.com, or 412-263-1699






Comments
Welcome to Post-Gazette subscriber-only commenting community. Please review our community guidelines.